Inclusion Criteria:

- Histologically confirmed CRC with evidence of locally advanced recurrent or
metastatic disease and measurable tumor lesions

- Life expectancy > 3 months

- For patients of reproductive potential (males and females), use of reliable means for
contraception throughout the trial and for 6 months following their final exposure to
study treatment

- Willingness and capability to be accessible for study follow-up

Exclusion Criteria:

- Prior 5-FU, capecitabine, and/or oxaliplatin treatment with the exception of: prior
oxaliplatin treatment≤ 6 weeks in the advanced or metastatic setting; prior treatment
with 5-FU, capecitabine, and/or oxaliplatin in the adjuvant setting if relapse
occurred > 6 months from concluding adjuvant therapy

- Peripheral neuropathy Grade ≥ 2

- Prior radiotherapy to a measurable metastatic lesion(s) to be used for response
assessment, unless the lesion has progressed subsequent to the radiotherapy

- Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1, or
radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle
1, Day 1

- Chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to Cycle 1, Day
1

- Evidence of clinically detectable ascites

- Other invasive malignancies within 5 years prior to Cycle 1, Day 1

- History or evidence upon physical examination of active central nervous system (CNS)
disease

- Current or recent participation in another experimental drug study

- Clinically significant cardiovascular disease, New York Heart Association (NYHA)
Grade II or greater congestive heart failure, serious cardiac arrhythmia within 1
year prior to Cycle 1, Day 1, or Grade II or greater peripheral vascular disease

- Active infection requiring parenteral antibiotics

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Cycle 1, Day 1, fine needle aspirations within 7 days prior to Cycle 1, Day
1, or anticipation of need for major surgical procedure during the course of the
study

- Known or suspected to be positive for the human immunodeficiency virus (HIV)

- Known to be positive for hepatitis C or hepatitis B surface antigen

- Inadequately controlled hypertension

- Prior history of hypertensive crisis or hypertensive encephalopathy

- History of arterial thromboembolic event 6 months prior to Cycle 1, Day 1

- History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Cycle 1, Day 1

- Bleeding diathesis or coagulopathy

- Pregnancy (positive pregnancy test) or breast feeding

- Serious, non-healing wound, ulcer, or bone fracture